Media

Oncopeptides publishes Q2 report 2025

Intervacc’s distribution partner Dechra launches Strangvac in Spain, Portugal and Slovenia

Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)

Oncopeptides – Invitation to presentation of the Q2 report 2025

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

SynOx Therapeutics Completes Enrollment in Registrational Phase 3 TANGENT Clinical Trial Significantly Ahead of Timeline

Oncopeptides Partners with SD Pharma to further broaden Pepaxti reach in Spain

Precirix Announces FDA Acceptance of Investigational New Drug (IND) Application for CAM-FAP-Ac-225

Oncopeptides announces acceptance of Spanish and Italian Real-World data at IMS Annual Meeting